الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 132 |  |  |
| | | from | 132 | | |
Abstract
The TP53 codon 72 polymorphism one of the prognostic and predictive markers for treatment decisions in CLL patients. The current study was conducted at the Oncology Center at Mansoura University Hospital (OCMU) between 2019 and 2021 on 100 CLL patients and 87 controls. All patients were subjected to clinical and radiological examination ,Complete blood count (CBC), Differential leukocytic count, blood film for smudge cell and prolymph counting, LDH and ESR, immunophenotypic markers assay and molecular assay. We assessed TP53 codon 72 polymorphism by RFLP pcr and Risk stratify of CLL patients according to clinicopathological data, the available lab work up . Our results can suggest that Pro/ Pro genotype contributes to increased susceptibility to CLL and Pro/ Pro genotype tends to be associated significantly with male gender, CD38 expression, and 17 p deletion while no association was found between TP53 72 Arg/ Pro and age, clinical presentation, staging, and hematological parameters, indicating that Pro/ Pro genotype could be used as a poor prognostic marker for our CLL patients. The smudge cell percentage associated with lymphocytic count significantly .We found a significant association between CD38 expression and their need to treatment in addition to CD38 positivity correlation with P53 Pro/Pro allele.